Stay updated with breaking news from Fibrogen Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The
Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic castration-resistant prostate cancer.
-- FibroGen said late Tuesday it saw encouraging data from a Fortis Therapeutics-sponsored phase 1 study of FG-3246 for patients with metastatic castration-resistant prostate cancer whose tumors...
-- View said late Tuesday that it received approval from key shareholders for a balance sheet restructuring plan. Shares slumped about 60%, with intraday trading volume at over 1.1 million versus a...